 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...161162163164165166167168169170171...208209» |
- | AiTan (rivoceranib) / HLB Bio Group
Journal: Advanced Hepatocellular Carcinoma With Hepatic Arterioportal Shunts: Combination Treatment of Transarterial Chemoembolization With Apatinib. (Pubmed Central) - Dec 22, 2020
In the TACE-apatinib group, the grade 3 apatinib-related adverse events occurred in four patients. TACE-apatinib was an efficacious and safe treatment for patients with advanced HCC with APS, and apatinib improved the efficacy of TACE in the treatment of these patients.
- ||||| retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma
New P1/2 trial: SHR-1701-II-203: A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Dec 22, 2020
P1/2, N=222, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- ||| Irene (pyrotinib) / Jiangsu Hengrui Pharma
New P1 trial: Drug-Drug Interaction of Pyrotinib With a Moderate CYP3A Inducer (clinicaltrials.gov) - Dec 22, 2020
P1, N=120, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- ||||||| famitinib (SHR 1020) / Jiangsu Hengrui Pharma
Trial completion: Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma?FACT? (clinicaltrials.gov) - Dec 21, 2020
P3, N=543, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
TACE-apatinib was an efficacious and safe treatment for patients with advanced HCC with APS, and apatinib improved the efficacy of TACE in the treatment of these patients. Active, not recruiting --> Completed
- | Hansoh Xinfu (flumatinib) / Jiangsu Hengrui Pharma, Jiangsu Hansoh Pharma
New P4 trial: Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure (clinicaltrials.gov) - Dec 20, 2020
P4, N=200, Not yet recruiting, Sponsor: Shenzhen Second People's Hospital
- | SHR7390 / Jiangsu Hengrui Pharma
New P2 trial, Metastases: SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (clinicaltrials.gov) - Dec 20, 2020
P2, N=10, Not yet recruiting, Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- || AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC) (clinicaltrials.gov) - Dec 20, 2020
P2, N=20, Recruiting, Sponsor: Shandong Cancer Hospital and Institute
- ||| Opdivo (nivolumab) / Ono Pharma, BMS
Clinical, Journal, Adverse events, Checkpoint inhibition: Landscape of immune checkpoint inhibitor-related adverse events in Chinese population. (Pubmed Central) - Dec 20, 2020
ICI-related AEs were generally mild and tolerable for a predominantly Chinese cohort. However, we should pay attention to the combination of ICI with chemotherapy as it could increase grade 3-5 TRAEs and irAEs.
- |||| Neulasta (pegfilgrastim) / Amgen, Kyowa Hakko Kirin, Roche, plinabulin (BPI 2358) / BeyondSpring
Clinical: The combination of plinabulin and pegfilgrastim was 53% more effective in reducing the incidence of profound neutropenia compared with pegfilgrastim alone in patients undergoing chemotherapy. @BlayneyDouglas @StanfordMed @SABCSSanAntonio #SABCS20 https://t.co/ZPY02t7wnK (Twitter) - Dec 19, 2020
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
Retrospective data, Journal: Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study. (Pubmed Central) - Dec 19, 2020
Along with AFP, the absence of main PVTT was an independent predictive factor for survival at uni- and multivariate analysis. Camrelizumab and apatinib yielded a promising outcome in patients with advanced HCC who developed a tumor thrombus in the first lower-order portal vein branches and was generally safe and had manageable side effects.
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P3 trial: A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Dec 19, 2020
P3, N=401, Not yet recruiting, Sponsor: RenJi Hospital
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial, Tumor mutational burden, PD(L)-1 Biomarker: Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer (clinicaltrials.gov) - Dec 19, 2020
P2, N=46, Not yet recruiting, Sponsor: Henan Cancer Hospital
- || AiRuiEn (rezvilutamide) / Jiangsu Hengrui Pharma
New P1 trial: The DDI Study Had Been Designed to Investigate the Effect of SHR3680 on the Pharmacokinetics of Midazolam, S-Warfarin and Omeprazole (clinicaltrials.gov) - Dec 19, 2020
P1, N=18, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Kadcyla (ado-trastuzumab emtansine) / Roche, pyrotinib (SHR-1258) / Jiangsu Hengrui Medicine, Gilotrif (afatinib) / Boehringer Ingelheim
[VIRTUAL] Clinical Management of Lung Adenocarcinoma Patients With HER2 V659E Mutation (Scientific Program Auditorium) - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_1861;
We revealed the prevalence of ERBB2 V659E in Chinese LUAD patients and elucidated the genomic profile of ERBB2 V659E mutant. This study paves avenue for the utilization of the novel HER2 inhibitors pyrotinib in ERBB2 V659E mutant LUAD patients.
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] Apatinib Monotherapy or Plus Chemotherapy for ES-SCLC After First-Line Standard Treatment Failure: An Exploratory Study () - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_1660;
This study paves avenue for the utilization of the novel HER2 inhibitors pyrotinib in ERBB2 V659E mutant LUAD patients. The abstract for this presentation is currently under embargo or has not been submitted.
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] Clinical Efficacy Analysis of Apatinib as a Second-Or Further-Line Treatment in Patients With Advanced NSCLC (ePoster Hall) - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_1607;
ECOG score is the influencing factor of median PFS. For patients with ECOG score of 0-1, oral apatinib 250mg per day therapy can show a better therapeutic effect.
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] Continuous Administration of Low-Dose Apatinib Combined With WBRT for Non-Small Cell Lung Cancer With Symptomatic Brain Metastases (ePoster Hall) - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_1603;
Conclusion This retrospective study suggests that NSCLC patients with multiple brain metastases treated with apatinib combined with WBRT, achieved encouraging therapeutic effects, showed a significant reduction in tumor size and peritumoral edema, enjoyed an improved KPS score and experienced prolonged survival time. Apatinib combined with WBRT is well tolerated and may be a potential choice for relapsed or drug-resistant advanced NSCLC patients with symptomatic multiple brain metastases.
- AiTan (rivoceranib) / HLB Bio Group, pyrotinib (SHR-1258) / Jiangsu Hengrui Medicine
[VIRTUAL] Pyrotinib Combined with Apatinib for HER2-Mutant Non-Small Cell Lung Cancer: Interim Analysis from a Phase II Clinical Study (ePoster Hall) - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_1581;
No treatment-related deaths were reported. Patient characteristics at baseline and response for pyrotinib with apatinib Conclusion Pyrotinib in combination with apatinib showed favorable antitumor activity and acceptable safety in heavily pretreated NSCLC patients with diverse HER2 mutations.
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] SHR-1210 (a PD-1 Blocker) plus Apatinib as a Neoadjuvant Therapy for Resctable IB-IIIA NSCLC: A Single-Arm, Exploratory Research () - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_1535;
Patient characteristics at baseline and response for pyrotinib with apatinib Conclusion Pyrotinib in combination with apatinib showed favorable antitumor activity and acceptable safety in heavily pretreated NSCLC patients with diverse HER2 mutations. The abstract for this presentation is currently under embargo or has not been submitted.
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Efficacy of Camrelizumab (SHR-1210) Plus Apatinib in Advanced NSCLC with EGFR Mutation (ePoster Hall) - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_1534;
P2
Table 1. Efficacy of camrelizumab and apatinib combination treatment in advanced NSCLC pts with EGFR mutation Conclusion Camrelizumab plus apatinib showed a moderate benefit in pts with EGFR mutated NSCLC and showed better efficacy in pts with EGFR 20ins or L858R mutation sub-types, warrant further investigation.
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Updated Survival and Biomarker Analysis of Camrelizumab and Apatinib in Previously Treated pts of Advanced Non-Squamous NSCLC (ePoster Hall) - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_1530;
P2, P3
The most common treatment-related adverse events of grade 3 or higher were hypertension (18 [17.1%]), palmar-plantar erythrodysesthesia syndrome (14 [13.3%]), and increased gamma-glutamyltransferase (10 [9.5%]). Conclusion Combined camrelizumab and apatinib had promising antitumor activity and acceptable safety in previously treated patients with advanced non-squamous NSCLC, especially in these with STK11 or KEAP1 mutation, phase III trial is ongoing for further validation (NCT04203485).
- AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Camrelizumab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy and Camrelizumab Maintenance Therapy in Advanced NSCLC () - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_1526;
Conclusion Combined camrelizumab and apatinib had promising antitumor activity and acceptable safety in previously treated patients with advanced non-squamous NSCLC, especially in these with STK11 or KEAP1 mutation, phase III trial is ongoing for further validation (NCT04203485). The abstract for this presentation is currently under embargo or has not been submitted.
- AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Efficacy and Safety of Camrelizumab in Patients with Advanced Lung Cancer: A Multicentre, Prospective, Observational Study. (ePoster Hall) - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_1519;
Conclusion In real life setting, camrelizumab demonstrated favorable efficacy and tolerable toxicity among patients with advanced lung cancer in China, and we expect follow-up data to provide more clues. [ChiCTR1900026089]
- AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Updated OS and Time to Second Progression with First-Line Camrelizumab Plus Chemo vs Chemo for Advanced Non-Squamous NSCLC (ePoster Hall) - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_1508;
P3
No new safety signal was observed. This combination represents a potential standard first-line therapy for these patients.
- AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Real-World Outcomes of Camrelizumab (SHR-1210) in Treating Advanced Non-Small Cell Lung Cancer: A Multicenter Prospective Study (ePoster Hall) - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_1490;
Camrelizumab monotherapy or in combination with chemotherapy and/or antiangiogenic agent were proved to be effective and safe in advanced NSCLC patients. Further study with a larger sample size is needed to explore the most potential camrelizumab-based therapeutic regimen for NSCLC patients.
- AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Camrelizumab Umbrella Trial Based on PD-L1 Expression: OS and PFS2 in Pre-Treated Advanced NSCLC (ePoster Hall) - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_1489;
P2
Patients with positive PD-L1 expression derived greater benefit from camrelizumab. These data supported the long-term outcome of camrelizumab as the second-line therapy in advanced/metastatic NSCLC.
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] Analysis of Efficacy and Safety of First Generation EGFR-TKI plus Apatinib in Treating Advanced NSCLC after EGFR-TKI Treatment Failure (ePoster Hall) - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_1429;
Conclusion The first generation EGFR-TKI plus Apatinib is efficacious in treating patients with advanced lung adenocarcinoma with EGFR-sensitive mutations after EGFR-TKI treatment failure, PFS2 is extended and with acceptable toxic effects. Brain metastasis is one of the factors with poor prognosis in patients with advanced lung adenocarcinoma.
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] Clinical Study of Apatinib Combined with Radiation Therapy in Advanced Non-small Cell Lung Cancer Patients with Brain Metastasis (ePoster Hall) - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_1402;
P2
Conclusion Apatinib combined with radiation therapy shown a good clinical efficacy and safety in advanced NSCLC pts with brain metastasis. Patient's quality of life and the compliance of therapy had been increased by oral drugs based on radiation therapy.
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] Apatinib Combined with Chemotherapy in First-Line Patients with Extensive-Stage Small-Cell Lung Cancer () - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_1131;
Patient's quality of life and the compliance of therapy had been increased by oral drugs based on radiation therapy. The abstract for this presentation is currently under embargo or has not been submitted.
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] Apatinib Combined With Irinotecan in the Treatment of Small Cell Lung Cancer: A Phase 2, Single-Arm, Prospective Study () - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_1112;
The abstract for this presentation is currently under embargo or has not been submitted. The abstract for this presentation is currently under embargo or has not been submitted.
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] Evaluation and Treatment of Hand-Foot Syndrome Induced by Apatinib Combined with Anti-PD-1 Therapy in Advanced NSCLC () - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_848;
The abstract for this presentation is currently under embargo or has not been submitted. The abstract for this presentation is currently under embargo or has not been submitted.
- Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Baseline Nlr and Plr Could Predict Clinical Outcomes in Patients With NSCLC Treated With ICIs () - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_626;
Conclusion Dynamic changes of NLR and PLR were associated with clinical outcomes. NLR and PLR are simple, inexpensive and readily available biomarkers that could be used to help predict response to immunotherapy in patients with NSCLC.
- AiTan (rivoceranib) / HLB Bio Group, Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
[VIRTUAL] Anti-PD1 Inhibitors Combined With Anti-Angiogenesis Showed Superior Efficacy in Control of Malignant Pleural Effusion for NSCLC (ePoster Hall) - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_391;
Conclusion The combination of anti-PD1 with Apatinib demonstrates superior efficacy in controlling MPE for NSCLC patients. Large prospective studies are needed to confirm this finding.
- [VIRTUAL] Patients Experienced Pseudoprogression to Anti-PD-1/PD-L1 Inhibitor Have Better Response Than Those Without in Lung Cancer (ePoster Hall) - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_388;
Conclusion Patients who experienced pseudoprogression with IO have obviously longer PFS than those without. Further studies in larger cohort are needed to confirm this finding.
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] A Prospective Phase II Study of Apatinib Plus Chemotherapy for Pretreated Patients With Advanced Small Cell Lung Cancer (ePoster Hall) - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_335;
P2
Conclusion Apatinib plus single agent chemotherapy showed a promising efficacy and a good tolerance in patients with pretreated SCLC. Especially, apatinib 250mg per day was recommended in this clinical trial.
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] Apatinib Plus Etoposide as Third-Line or Further-Line Treatment for Extensive SCLC Patients: A Multicenter, Single Arm, Phase Ⅱ Clinical Trial () - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_332;
Especially, apatinib 250mg per day was recommended in this clinical trial. The abstract for this presentation is currently under embargo or has not been submitted.
- AiTan (rivoceranib) / HLB Bio Group, pyrotinib (SHR-1258) / Jiangsu Hengrui Medicine
[VIRTUAL] Pyrotinib Combined with Apatinib for HER2-Mutant Non-Small Cell Lung Cancer: Interim Analysis from a Phase II Clinical Study (Scientific Program Auditorium) - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_252;
No treatment-related deaths were reported. Patient characteristics at baseline and response for pyrotinib with apatinib Conclusion Pyrotinib in combination with apatinib showed favorable antitumor activity and acceptable safety in heavily pretreated NSCLC patients with diverse HER2 mutations.
- Avastin (bevacizumab) / Roche
[VIRTUAL] Oral VEGFR Inhibitor Monotherapy for Lung Cancer: Should We or Should We Not? (Scientific Program Auditorium) - Dec 17, 2020 - Abstract #IASLCWCLC2020IASLC_WCLC_244;
P3
In summary, anlotinib as single agent is a treatment option for pretreated patients with advanced NSCLC. Monotherapy with other VEGFR TKIs is not recommended.
- | AiTan (rivoceranib) / HLB Bio Group
Journal: Apatinib exhibits cytotoxicity toward leukemia cells by targeting VEGFR2-mediated prosurvival signaling and angiogenesis. (Pubmed Central) - Dec 17, 2020
Monotherapy with other VEGFR TKIs is not recommended. Apatinib exerts antileukemia effects by targeting VEGFR2-induced prosurvival signaling and angiogenesis, thus providing a rationale for the application of apatinib in AML.
- | ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Acacia Pharma
Journal: Psychomotor Recovery Following Remimazolam-Induced Sedation and the Effectiveness of Flumazenil as an Antidote. (Pubmed Central) - Dec 17, 2020
P1
The moderate and short-lasting residual effect of remimazolam after 2-h conscious sedation proposes a need for psychomotor assessment(s) before hospital discharge. ClinicalTrials.gov identifiers: NCT01970072 and NCT03444480.
- || AiTan (rivoceranib) / HLB Bio Group
Clinical, Journal, Monotherapy: Apatinib Monotherapy for Chemotherapy-Refractory Metastatic Colorectal Cancer: A Multi-centre, Single-Arm, Prospective Study. (Pubmed Central) - Dec 17, 2020
Previous anti-angiogenic therapies did not influence outcomes. Baseline NLR, early CA19-9 decrease, and HFS could predict the efficacy of apatinib.
- edralbrutinib (TG-1701) / TG Therap
New P2 trial: An Open Label Study of the Effects of SHR1459 in NMOSDs Patients (clinicaltrials.gov) - Dec 16, 2020
P2, N=10, Not yet recruiting, Sponsor: Reistone Biopharma Company Limited
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line Immunotherapy (clinicaltrials.gov) - Dec 16, 2020
P2, N=30, Not yet recruiting, Sponsor: Junling Li
- || AiTan (rivoceranib) / HLB Bio Group
Clinical, Review, Journal: Comprehensive treatment for multicentric giant cell tumors of the pelvis and spine using apatinib: A case report and literature review. (Pubmed Central) - Dec 16, 2020
Comprehensive treatment including apatinib represents a potential new treatment strategy for inoperable GCTB, with tolerable side effects. However, further clinical trials are now necessary to confirm an effective dose and determine the efficacy and safety of apatinib in the treatment of GCTB.
- | AiTan (rivoceranib) / HLB Bio Group
Journal: Transarterial chemoembolization combined with apatinib versus transarterial chemoembolization alone for hepatocellular carcinoma with macroscopic vascular invasion: A propensity score matching analysis. (Pubmed Central) - Dec 16, 2020
The OS hazard ratio for the choice of TACE-apatinib treatment compared to TACE treatment alone was 0.50 (95% confidence interval: 0.28-0.90; P = 0.021). TACE combined with apatinib may result in superior OS compared to TACE therapy alone for HCC patients with macrovascular invasion.
- || AiTan (rivoceranib) / HLB Bio Group
Clinical, Retrospective data, Journal: Transcatheter arterial chemoembolization combined with low-dose apatinib in the treatment of unresectable hepatocellular carcinoma in elderly patients: Efficacy and safety. (Pubmed Central) - Dec 16, 2020
TACE combined with low-dose apatinib provides an alternative treatment option for elderly patients with unresectable HCC. Our clinical study has proven its safety and efficacy.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Trial completion date, Trial primary completion date: Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC (clinicaltrials.gov) - Dec 16, 2020
P=N/A, N=200, Not yet recruiting, Sponsor: Shandong Cancer Hospital and Institute
Our clinical study has proven its safety and efficacy. Trial completion date: Oct 2021 --> Jun 2022 | Trial primary completion date: Aug 2021 --> Dec 2021
- |||||||||| Ruiqin (henagliflozin) / Jiangsu Hengrui Pharma, Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
New P3 trial, Monotherapy: Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy (clinicaltrials.gov) - Dec 13, 2020
P3, N=760, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - Dec 13, 2020
P2, N=38, Recruiting, Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
- || AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
New P1 trial: Study to Investigate Relative Bioavailability of Different Formulations of SHR6390 in Healthy Subjects (clinicaltrials.gov) - Dec 13, 2020
P1, N=24, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.